What types of cancer are Sorafenib/Nexavar used to treat?

Sorafenib/Nexavar (Sorafenib) is a small molecule multi-target tyrosine kinase inhibitor developed by Bayer. It has a long history of application in the field of tumor treatment and is one of the first targeted drugs approved for the treatment of solid tumors in the world. Its unique feature is that it not only acts on the proliferation signaling pathway of tumor cells, but also interferes with tumor angiogenesis, thereby achieving a dual inhibitory effect. This mechanism of action makes it useful in a variety of solid tumors.

From the perspective of indications, the most classic and widely used indication of sorafenib is advanced hepatocellular carcinoma. As the world's first targeted drug proven to have clear efficacy in liver cancer patients, Nexavar was once hailed as the "beginning of targeted therapy for liver cancer." Prior to this, there was almost no systematic drug treatment for advanced liver cancer, and the launch of sorafenib provides patients with new hope. Secondly, it is also approved for the treatment of advanced renal cell carcinoma, especially after traditional interferon or interleukin treatment fails, sorafenib provides patients with a new drug option. In addition, sorafenib is also used in differentiated thyroid cancer, especially for patients refractory to radioactive iodine, where it can delay the progression of the disease to a certain extent.

It is worth noting that although sorafenib is called a multi-target drug, it is not suitable for use in all cancer types. Its application is mainly concentrated in hepatocellular carcinoma, renal cell carcinoma and thyroid cancer, which are highly angiogenesis-dependent or driven by related signaling pathways. In global clinical practice, sorafenib has gradually become one of the standard regimens for the treatment of these tumors. With the subsequent emergence of more new-generation targeted drugs and immunotherapy, the market position of sorafenib has been adjusted, but it is still an irreplaceable basic drug in the treatment system for liver cancer and other diseases.

Reference materials:https://www.nexavar.com/